Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
Fiche publication
Date publication
janvier 2024
Journal
Inflammatory bowel diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, Redondo I, Escobar R, Gibble TH, Keohane A, Morris N, Zhang X, Arora V, Kobayashi T
Lien Pubmed
Résumé
Efficacy and safety of mirikizumab, a p19-targeted anti-interleukin-23 monoclonal antibody, for moderately to severely active ulcerative colitis was demonstrated previously. We evaluated clinical response, baseline characteristics, and clinical status in patients not responding by 12 weeks (W) of induction who then received extended induction treatment.
Mots clés
IL-23 antibodies, extended induction, mirikizumab, ulcerative colitis
Référence
Inflamm Bowel Dis. 2024 01 25;: